Acetaldehyde
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
Acetaldehyde: Drug Repurposing Evaluation Report
One-Sentence Summary
Acetaldehyde (ethanal) is a reactive aldehyde best known as a toxic intermediate of ethanol metabolism and a Group 1 carcinogen, rather than an established therapeutic agent. The TxGNN model returned no predicted indications for this compound, and no regulatory approvals or safety records are available in the current evidence pack. This report cannot advance to a standard repurposing evaluation without foundational data remediation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not established |
| Predicted New Indication | No prediction available |
| TxGNN Prediction Score | — |
| Evidence Level | L5 (no predictions returned) |
| Market Status | Not marketed |
| Number of Approvals | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Mechanism of action data is currently unavailable, and the TxGNN model returned no drug repurposing candidates for Acetaldehyde. From known biochemistry, Acetaldehyde (CH₃CHO) is the primary oxidative metabolite of ethanol produced by alcohol dehydrogenase (ADH), and is itself further oxidised to acetate by aldehyde dehydrogenase (ALDH). Its high chemical reactivity (it forms protein adducts and DNA adducts) underpins both its toxicity and its classification by IARC as a Group 1 carcinogen.
Because no therapeutic indication has been established and no TxGNN prediction was generated, a mechanism-to-indication bridge analysis cannot be completed. It is worth noting that the related compound paraldehyde (a cyclic trimer that releases acetaldehyde upon hydrolysis) does carry historical therapeutic approvals as a sedative/anticonvulsant — if the intended query target is paraldehyde or another acetaldehyde-releasing prodrug, the pipeline should be re-run with the corrected entity.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN model produced no repurposing predictions for Acetaldehyde, no regulatory approvals exist, and all safety data fields are empty — the minimum evidence threshold for any repurposing pathway has not been met.
To proceed, the following is needed:
- Clarify drug entity: Confirm whether the intended subject is Acetaldehyde itself or a related compound (e.g., paraldehyde, chloral hydrate, or disulfiram — which elevates acetaldehyde levels) that may have an established DrugBank entry and therapeutic profile
- Obtain DrugBank ID and MOA: Resolve Data Gap DG002 by querying DrugBank with the corrected entity name
- Re-run TxGNN prediction: After confirming correct entity mapping, resubmit to the prediction pipeline to generate candidate indications
- Obtain safety data: Source package insert warnings and contraindications from the regulatory agency to resolve Data Gap DG001 before any safety evaluation
- Re-evaluate evidence level: Once predictions are available, re-classify evidence level (L1–L5) based on supporting clinical trials and literature
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.